Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med. 2017;4:227. doi:10.3389/fmed.2017.00227
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–4434. doi:10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar
• Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple negative breast cancer: treatment challenges and solutions. Breast Cancer. 2016;8:93–107. doi:10.2147/BCTT.S69488
   PubMedGoogle Scholar
• Mirzania M. Approach to the triple negative breast cancer in new drugs area. Int J Hematol Oncol Stem Cell Res. 2016;10:115–119.
   Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–1281. doi:10.1200/JCO.2007.14.4147
   PubMed Web of Science ®Google Scholar
• Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193–216. doi:10.1146/annurev.bi.48.070179.001205
   PubMed Web of Science ®Google Scholar
• Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L, Waterfield MD. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res. 1986;46(1):285–292.
   Web of Science ®Google Scholar
• Shao Q, Zhu W. Ligand binding effects on the activation of the EGFR extracellular domain. Phys Chem Chem Phys. 2019;21(15):8141–8151. doi:10.1039/C8CP07496H
   Web of Science ®Google Scholar
• Shukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci. 2011;102:1032–1037. doi:10.1111/j.1349-7006.2011.01887.x
   PubMed Web of Science ®Google Scholar
• Harandi A, Zaidi AS, Stocker AM, et al. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009;2009:567486. doi:10.1155/2009/567486
   PubMedGoogle Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. doi:10.1056/NEJMoa040938
   PubMed Web of Science ®Google Scholar
• Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397–406. doi:10.1007/s10549-018-4697-y
   PubMed Web of Science ®Google Scholar
• Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, et al. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: a systematic review and a meta-analysis. Cancer Treat Rev. 2018;62:1–8. doi:10.1016/j.ctrv.2017.10.008
   PubMed Web of Science ®Google Scholar
• Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8:1483–1507. doi:10.1007/s13346-018-0551-3
   PubMed Web of Science ®Google Scholar
• Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005;23:5323–5333. doi:10.1200/JCO.2005.08.326
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293. doi:10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• O’Regan R, Hawk NN. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin Ther Targets. 2011;15(7):859–872. doi:10.1517/14728222.2011.575362
   PubMed Web of Science ®Google Scholar
• Liu T, Yacoub R, Taliaferro-Smith LD, et al. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther. 2011;10:1460–1469. doi:10.1158/1535-7163.MCT-10-0925
   PubMed Web of Science ®Google Scholar
• You KS, Yi YW, Cho J, Park JS, Seong YS. Potentiating therapeutic effects of epidermal growth factor receptor inhibition in triple-negative breast cancer. Pharmaceuticals. 2021;14(6):589. doi:10.3390/ph14060589
   Web of Science ®Google Scholar
• Costa R, Shah AN, Santa-Maria CA, et al. Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development. Cancer Treat Rev. 2017;53:111–119. doi:10.1016/j.ctrv.2016.12.010
   PubMed Web of Science ®Google Scholar
• El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep. 2020;10(1):6367. doi:10.1038/s41598-020-63310-2
   PubMed Web of Science ®Google Scholar
• Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR, Boerner JL. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. Breast Cancer Res Treat. 2014;147(2):283–293. doi:10.1007/s10549-014-3102-8
   Web of Science ®Google Scholar
• El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells. Mol Carcinog. 2017;56:1383–1394. doi:10.1002/mc.22596
   Web of Science ®Google Scholar
• El Guerrab A, Bamdad M, Kwiatkowski F, Bignon YJ, Penault-Llorca F, Aubel C. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple negative breast cancer. Oncotarget. 2016;7(45):73618–73637. doi:10.18632/oncotarget.12037
   Google Scholar
• Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet Genomics. 2006;16:475–483. doi:10.1097/01.fpc.0000220562.67595.a5
   PubMed Web of Science ®Google Scholar
• Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with IGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer. 2008;98(5):923–930. doi:10.1038/sj.bjc.6604269
   Web of Science ®Google Scholar
• Herberger B, Berger W, Puhalla H, et al. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer: cells. Mol Cancer Ther. 2009;8:1547–1556. doi:10.1158/1535-7163.MCT-09-0003
   Web of Science ®Google Scholar
• You KS, Yi YW, Kwak SJ, Seong YS. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells. Int J Oncol. 2018;52(3):828–840. doi:10.3892/ijo.2018.4244
   Web of Science ®Google Scholar
• Wang Z, Feng X, Molinolo AA, et al. 4E-BP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer. Cancer Res. 2019;79(7):1438–1450. doi:10.1158/0008-5472.CAN-18-1220
   PubMed Web of Science ®Google Scholar
• Musa J, Orth MF, Dallmayer M, et al. Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis. Oncogene. 2016;35(36):4675–4688. doi:10.1038/onc.2015.515
   Web of Science ®Google Scholar
• Sekiyama N, Arthanari H, Papadopoulos E, Rodriguez-Mias RA, Wagner G, Léger-Abraham M. Molecular mechanism of the dual activity of 4EGI-1: dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1. Proc Natl Acad Sci U S A. 2015;112(30):E4036–E4045. doi:10.1073/pnas.1512118112
   Web of Science ®Google Scholar
• Sikalidis AK, Mazor KM, Kang M, Liu H, Stipanuk MH. Total 4EBP1 is elevated in liver of rats in response to low sulfur amino acid intake. J Amino Acids. 2013;2013:864757. doi:10.1155/2013/864757
   Google Scholar
• Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle. 2012;11(3):594–603. doi:10.4161/cc.11.3.19096
   PubMed Web of Science ®Google Scholar
• Choo AY, Yoon S-O, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA. 2008;105(45):17414–17419. doi:10.1073/pnas.0809136105
   PubMed Web of Science ®Google Scholar
• Ducker GS, Atreya CE, Simko JP. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014;33(12):1590–1600. doi:10.1038/onc.2013.92
   PubMed Web of Science ®Google Scholar
• Mi W, Ye Q, Liu S, She Q-B. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Oncotarget. 2015;6(16):13962–13977. doi:10.18632/oncotarget.3920
   PubMed Web of Science ®Google Scholar
• Xu XH, Chen YC, Xu YL, et al. Garcinone E blocks autophagy through lysosomal functional destruction in ovarian cancer cells. World J Tradit Chin Med. 2021;7:209–216.
   Google Scholar
• Wei MM, Wang SS, Zheng JL, et al. Herbal medicine Teng-Long-bu-zhong-tang inhibits the growth of human RKO colorectal cancer by regulating apoptosis, senescence, and angiogenesis. World J Tradit Chin Med. 2022;8:110–114. doi:10.4103/wjtcm.wjtcm_42_21
   Google Scholar
• Rabbani F, Yazdiniapour Z, Ghanadian M, Zolfaghari B, Maleki M, Shafiee F. Cytotoxicity and apoptosis assay of novel cyclomyrsinol diterpenes against breast cancer cell lines. World J Tradit Chin Med. 2022;8:273–277. doi:10.4103/wjtcm.wjtcm_6_21
   Google Scholar